Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6039803 | 0.83 | CA2 (0.46) | ESR1S1PR1MAPTLMNAL3MBTL1 | |
| SCHEMBL3164442 | 0.83 | ESR1 (0.64) | ESR1S1PR1MAPTRAB9AC5AR1 | |
| SCHEMBL9435456 | 0.81 | ESR1 (0.54) | ESR1S1PR1MAPTRAB9AC5AR1 | |
| SCHEMBL9435464 | 0.80 | CA2 (0.39) | ESR1S1PR1MAPTLMNAL3MBTL1 | |
| SCHEMBL6063203 | 0.80 | ESR1 (0.79) | ESR1S1PR1MAPTRAB9AC5AR1 | |
| SCHEMBL3376825 | 0.75 | ESR1 (0.54) | ESR1MAPTRAB9ALMNAL3MBTL1 | |
| SCHEMBL28722339 | 0.74 | C5AR1 (0.76) | ESR1S1PR1RAB9AC5AR1LMNA | |
| SCHEMBL23859846 | 0.72 | RORC (0.46) | ESR1L3MBTL1CA2KMT2AKDM4E | |
| SCHEMBL7835577 | 0.72 | CA2 (0.41) | ESR1S1PR1RAB9ALMNACA2 | |
| SCHEMBL6039797 | 0.72 | CA2 (0.41) | ESR1RAB9ALMNAL3MBTL1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078537-B2 | Phenylalkyl diamine and amide analogs | SK CORPORATION (KR) | 2006-07-18 | — | — | US | claimed |
| EP-1401821-A4 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK CORP (KR) | 2006-05-31 | — | — | EP | claimed |
| EP-1401821-A1 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK Corporation (KR) | 2004-03-31 | — | — | EP | claimed |
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2003-06-05 | — | — | US | claimed |
| WO-2002100848-A1 | NOVEL PHENYLALKYL DIAMINE AND AMIDE ANALOGS | SK CORPORATION (KR) | 2002-12-19 | — | — | WO | claimed |
| EP-1183232-B1 | MONOFLUOROALKYL DERIVATIVES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7135487-B2 | such as N-2-(4-Bromophenyl)propyl methanesulfonamide; sulfonamidation of the amine; glutamate receptor potentiators | ELI LILLY AND COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-7034045-B1 | Monofluoroalkyl derivatives | ELI LILLY AND COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | ARNOLD MACKLIN B | 2006-02-09 | — | — | US | disclosed |
| US-6911476-B2 | Sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-06-28 | — | — | US | disclosed |
| EP-1528055-A2 | Sulphonamide Derivatives | Eli Lilly & Company (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-0860428-B1 | Sulphonamide derivatives | LILLY CO ELI (US) | 2004-12-08 | — | — | EP | disclosed |
| WO-1998033496-A1 | SULPHONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1998-08-06 | — | — | WO | disclosed |
| US-5776981-A | Use of acyl urea compounds for controlling endoparasites and ectoparasites of warm-blooded animals | NOVARTIS CORPORATION (US) | 1998-07-07 | — | — | US | disclosed |
| US-5776982-A | Use of acyl urea compounds for controlling endoparasites and ectoparasites of warm-blooded animals | NOVARTIS CORPORATION (US) | 1998-07-07 | — | — | US | disclosed |
| US-5420163-A | Insecticides or miticides | CIBA-GEIGY (US) | 1995-05-30 | — | — | US | disclosed |
| US-5135953-A | Oral or injections; cattle, swine, poultry | CIBA-GEIGY (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0211004-A1 | USE OF ACYL UREA COMPOUNDS FOR CONTROLLING ENDOPARASITES AND ECTOPARASITES OF WARM-BLOODED ANIMALS | RHONE-POULENC NEDERLAND B.V. (NL) | 1987-02-25 | — | — | EP | disclosed |
| WO-1986003941-A1 | USE OF ACYL UREA COMPOUNDS FOR CONTROLLING ENDOPARASITES AND ECTOPARASITES OF WARM-BLOODED ANIMALS | UNION CARBIDE CORPORATION (US) | 1986-07-17 | — | — | WO | disclosed |
| US-3860723-A | METHODS AND COMPOSITIONS FOR INCREASING FEED INTAKE OF ANIMALS | SMITHKLINE BECKMAN CORPORATION | 1975-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030599-A1 | SULPHONAMIDE DERIVATIVES | GRIN2C, GLRA2, GLRA1 | ESR1 889/4885S1PR1 883/4885MAPT 4760/4885 |
| US-20030105079-A1 | Novel phenylalkyl diamine and amide analogs | SIGMAR1, TAAR1, OPRL1 | ESR1 1798/4885S1PR1 393/4885MAPT 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.